DUBLIN–(BUSINESS WIRE)–The “The 2020 Study of U.S. Market for Eye Health Supplements” report has been added to ResearchAndMarkets.com’s offering. The 2020 Study of Eye Health Supplements, part of the 2020 Study of Eye Health in the Digital Age, is de…
Author: Business Wire
NeurOptics Launches New NPi®-300 Automated Pupillometer
IRVINE, Calif.–(BUSINESS WIRE)–NeurOptics announced the U.S. launch of its NPi®-300, a next-generation automated pupillometer that enhances pupillary assessment.
OcuTerra Appoints Richard Lindstrom, M.D., and Sheri Rowen, M.D., to Scientific Advisory Board
BOSTON–(BUSINESS WIRE)–OcuTerra announces the appointments of Richard Lindstrom, M.D., and Sheri Rowen, M.D., to its Scientific Advisory Board
NovaBay Pharmaceuticals to Participate in Two July Investment Conferences
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market and CelleRx® for the beauty market, announces that management will participa…
Dry Eye Disease Clinical Landscape Report 2021-2029 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Dry Eye Disease” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the Dry Eye Disease market, comprising key marketed and pipeline drugs, recent events and a…
Riassunto: Il gruppo Polpharma Biologics annuncia che la sua joint venture Bioeq ha sottoscritto un accordo di commercializzazione del biosimilare di ranibizumab
VARSAVIA, Polonia–(BUSINESS WIRE)–Il gruppo Polpharma Biologics annuncia che Bioeq, la sua joint venture con Santo Holding (Strüngmann Group), ha perfezionato una collaborazione commerciale con Teva Pharmaceutical Industries Ltd. relativa al suo cand…
Polpharma Biologics Group annonce que sa coentreprise Bioeq a conclu un accord de mise sur le marché pour le biosimilaire du ranibizumab
VARSOVIE, Pologne–(BUSINESS WIRE)–Polpharma Biologics Group annonce que Bioeq, sa coentreprise avec Santo Holding (Strüngmann Group), a conclu un partenariat avec Teva Pharmaceutical Industries Ltd. pour la mise sur le marché de leur candidat biosimi…
Polpharma Biologics Group meldet Abschluss einer Vermarktungsvereinbarung für das Ranibizumab-Biosimilar durch ihr Joint-Venture-Unternehmen Bioeq
WARSCHAU, Polen–(BUSINESS WIRE)–Die Polpharma Biologics Group gibt bekannt, dass Bioeq, ein Joint Venture zwischen ihr und der Santo Holding (Strüngmann-Gruppe), eine kommerzielle Partnerschaft mit Teva Pharmaceutical Industries Ltd. für den Biosimil…
Samenvatting: Polpharma Biologics Group kondigt aan dat haar joint venture, Bioeq, een commercialiserings overeenkomst is aangegaan voor biosimilar Ranibizumab
WARSCHAU, Polen–(BUSINESS WIRE)–Polpharma Biologics Group kondigt aan dat haar joint venture met Santo Holding (Strüngmann Group), Bioeq, een commerciële samenwerking heeft gesloten met Teva Pharmaceutical Industries Ltd. voor hun biosimilar kandidaa…
Resumen: Polpharma Biologics Group anuncia que su empresa en participación Bioeq ha iniciado un acuerdo de comercialización para el fármaco biosimilar de ranibizumab
VARSOVIA, Polonia–(BUSINESS WIRE)–Polpharma Biologics Group anuncia que su empresa en participación con la empresa Santo Holding (Strüngmann Group), Bioeq, ha finalizado una colaboración comercial con Teva Pharmaceutical Industries Ltd. para el candi…
Two Prominent Optometric Practices Partner with Carolina Eyecare Physicians
CHARLESTON, S.C.–(BUSINESS WIRE)–Belle Hall Eye Care and Eyecare Specialties of Charleston, two Charleston-based optometric practices, have partnered with US EYE and Carolina Eyecare Physicians to enrich patient care and expand the group’s multi-disc…
Desktop Health Adds PhonoGraft Biofabrication Platform to Growing Technology Portfolio
NEWPORT BEACH, Calif.–(BUSINESS WIRE)– #3DP–Desktop Health to develop PhonoGraft technology, a 3D printed biofabrication solution that offers a promising pathway for soft tissue regeneration.
Polpharma Biologics Group Announces That Its Joint Venture Company, Bioeq, Has Entered Into a Commercialization Agreement for Biosimilar Ranibizumab
WARSAW, Poland–(BUSINESS WIRE)– #biologics–Polpharma Biologics Group announces that its joint venture company, Bioeq, has entered into a commercialization agreement for biosimilar Ranibizumab.
Now Delivered in a Bottle, Oasis TEARS® PF PLUS Preservative-Free Lubricant Eye Drops for the Relief of Dry Eye Symptoms
GLENDORA, Calif.–(BUSINESS WIRE)– #oasistears–OASIS® Medical Inc., manufacturer and distributor of SOFT PLUG® brand of punctal plugs and Oasis TEARS® Preservative-Free Lubricating Eye Drops is formally launching Oasis TEARS® PF PLUS preservative-fre…
jCyte Announces Appointment of Adrian Morris as Chief Development Officer
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the company’s executive management team with the …
Eyewear and Optical Retailers Database for Europe 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Eyewear and Optical Retailers in Europe” newsletter has been added to ResearchAndMarkets.com’s offering. For each country, similar rankings are provided covering all the major optical retailers. This database covers all ma…
Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
NEW YORK–(BUSINESS WIRE)–Iveric Bio announced that the Company received written agreement from the US FDA under a Special Protocol Assessment (SPA) for the design of GATHER2.
Glaucoma Research – Global Clinical Trials Review, H1, 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Glaucoma – Global Clinical Trials Review, H1, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This report presents top line data relating to the clinical trials on Glaucoma. Report includes an ov…
Worldwide Eye Care Industry to 2026 – Growing Prevalence of Different Ocular Problems is Driving Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Eye Care Market, By Product Type (Eyeglasses, Eye Drops, Contact Lens, Intraocular Lens, Eye Vitamins, Others), By Eye Drops (Prescription v/s Over-The-Counter), By Coating, By Lens Material, By Distribution Channel…
Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that the company was added to the broad-…